Aquinox Pharmaceuticals, Inc.

Canaccord Genuity is pleased to announce that on September 23, 2016, it completed an underwritten public offering of common shares for Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ: AQXP). Aquinox issued a total of 6,125,500 shares of common stock, at a price to the public of US$12.25 per share. Canaccord Genuity acted as joint bookrunner for the offering.

Aquinox intends to use the net proceeds from the offering to fund additional clinical development of AQX-1125 and to fund pre-commercial and market assessment activities, research and development costs to advance its pipeline of preclinical product candidates and for working capital and other general corporate purposes.

Aquinox is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.